Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis, a clinical-stage biotechnology company, showcased its Phase 2/3 COVA study results for severe Covid-19 at the World Congress on Infectious Diseases, held from June 24 to 26, 2024, in Paris.

Professor Valerie Pourcher presented the findings, emphasizing the study's relevance amid rising Covid-19 cases. Dr. Claudia Ferreira discussed the broader implications, highlighting a 52% increase in emergency room visits for Covid-19 in France during mid-June. She also chaired multiple roundtables.

The study, which focused on the efficacy of oral BIO101 (20-hydroxyecdysone) in adults hospitalized with severe Covid-19, showed promising results. There was a 43.8% reduction in early respiratory failure or death risk and a 44.6% decrease in the 90-day death rate.

Stanislas Veillet, CEO of Biophytis, noted that the COVA program positions BIO101 as a leading candidate for severe Covid-19 treatments, particularly beneficial for elderly patients with co-morbidities.